NCT02916537View on ClinicalTrials.gov

A Phase 1 Trial for Evaluation of the Safety, Pharmacokinetics, and [18F] Radiation Dosimetry of CTT1057

PHASE1CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

September 30, 2016

Primary Completion Date

August 28, 2017

Study Completion Date

August 28, 2017

Conditions
Prostate Cancer
Interventions
DRUG

CTT1057

Single IV dose (370 MBq, or 10 mCi) of CTT1057 followed by combined PET/MR imaging (prostate + whole body).

PROCEDURE

Prostatectomy

Radical prostatectomy with lymph node dissection

Trial Locations (1)

94143

University of California San Francisco, San Francisco

Sponsors
All Listed Sponsors
collaborator

University of California, San Francisco

OTHER

lead

Cancer Targeted Technology

INDUSTRY